Defining the clinical course of multiple sclerosis: The 2013 revisions

Neurology

Volumn 83, Issue 3, 2014, Pages 278-286

  Lublin, Fred D ^a   Reingold, Stephen C ^b   Cohen, Jeffrey A ^c   Cutter, Gary R ^d   Sørensen, Per Soelberg ^e   Thompson, Alan J ^f   Wolinsky, Jerry S ^g   Balcer, Laura J ^h   Banwell, Brenda ⁱ   Barkhof, Frederik ^j   Bebo Jr , Bruce ^k   Calabresi, Peter A ^l   Clanet, Michel ^m   Comi, Giancarlo ⁿ   Fox, Robert J ^c   Freedman, Mark S ^o   Goodman, Andrew D ^p   Inglese, Matilde ^a   Kappos, Ludwig ^q   Kieseier, Bernd C ^r   Lincoln, John A ^g   Lubetzki, Catherine ^s   Miller, Aaron E ^a   Montalban, Xavier ^t   O'Connor, Paul W ^u   Petkau, John ^v   Pozzilli, Carlo ^w   Rudick, Richard A ^c   Sormani, Maria Pia ^x   Stüve, Olaf ^y   Waubant, Emmanuelle ^z   Polman, Chris H ^j   more..

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Scientific and Clinical Review Associates LLC   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e Rigshospitalet   (Denmark)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

^g UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^h NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

ⁱ CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^j VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^k National Multiple Sclerosis Society   (United States)

^l JOHNS HOPKINS HOSPITAL   (United States)

^m CHU PURPAN   (France)

ⁿ VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^o OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^p UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^q UNIVERSITY HOSPITAL BASEL   (Switzerland)

^r HEINRICH HEINE UNIVERSITY   (Germany)

^s PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^t HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^u ST MICHAEL'S HOSPITAL   (Canada)

^v UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^w SAPIENZA UNIVERSITY OF ROME   (Italy)

^x Biostatistics Unit   (Italy)

^y UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^z UCSF Multiple Sclerosis Center   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL TRIALS AS TOPIC; CONSENSUS; HUMANS; MULTIPLE SCLEROSIS; SOCIETIES, MEDICAL;

EID: 84905819646     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000000560     Document Type: Review

References (31)

1. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 1996;46:907-911.
2. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011;69:292-302.
3. Miller D, Barkhof F, Montalban X, Thompson A, Filippi M. Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis. Lancet Neurol 2005;4:281-288.
4. Tintore M, Rovira A, Martinez MJ, et al. Isolated demyelinating syndromes: comparison of different MR imaging criteria to predict conversion to clinically definite multiple sclerosis. AJNR Am J Neuroradiol 2000;21:702-706.
5. O'Riordan JI, Thompson AJ, Kingsley DP, et al. The prognostic value of brain MRI in clinically isolated syndromes of the CNS: a 10-year follow-up. Brain 1998;121:495-503.
6. Filippi M, Horsfield MA, Morrissey SP, et al. Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis. Neurology 1994;44:635-641.
7. Morrissey SP, Miller DH, Kendall BE, et al. The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis: a 5-year follow-up study. Brain 1993;116:135-146.
8. Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis: CHAMPS Study Group. N Engl J Med 2000;343:898-904.
9. Comi G, Filippi M, Barkhof F, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001;357:1576-1582.
10. Kappos L, Polman CH, Freedman MS, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006;67:1242-1249.
11. Comi G, Martinelli V, Rodegher M, et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (Pre-CISe study): a randomised, double-blind, placebo-controlled trial. Lancet 2009;374:1503-1511.
12. Miller DH, Weinshenker BG, Filippi M, et al. Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler 2008;14:1157-1174.
13. Lebrun C, Bensa C, Debouverie M, et al. Association between clinical conversion to multiple sclerosis in radiologically isolated syndrome and magnetic resonance imaging, cerebrospinal fluid, and visual evoked potential: follow-up of 70 patients. Arch Neurol 2009;66:841-846.
14. Siva A, Saip S, Altintas A, Jacob A, Keegan BM, Kantarci OH. Multiple sclerosis risk in radiologically uncovered asymptomatic possible inflammatory-demyelinating disease. Mult Scler 2009;15:918-927.
15. Okuda DT, Mowry EM, Beheshtian A, et al. Incidental MRI anomalies suggestive of multiple sclerosis: the radiologically isolated syndrome. Neurology 2009;72:800-805.
16. Okuda DT, Mowry EM, Cree BA, et al. Asymptomatic spinal cord lesions predict disease progression in radiologically isolated syndrome. Neurology 2011;76:686-692.
17. Giorgio A, Stromillo ML, Rossi F, et al. Cortical lesions in radiologically isolated syndrome. Neurology 2011;77: 1896-1899.
18. Lassmann H, van Horssen J, Mahad D. Progressive multiple sclerosis: pathology and pathogenesis. Nat Rev Neurol 2012; 8:647-656.
19. Lassmann H, Bruck W, Lucchinetti CF. The immunopathology of multiple sclerosis: an overview. Brain Pathol 2007;17:210-218.
20. Ebers GC. Natural history of primary progressive multiple sclerosis. Mult Scler 2004;10(suppl 1):S8-S13.
21. Confavreux C, Vukusic S. Natural history of multiple sclerosis: a unifying concept. Brain 2006;129:606-616.
22. Thorpe JW, Kidd D, Moseley IF, et al. Serial gadoliniumenhanced MRI of the brain and spinal cord in early relapsing-remitting multiple sclerosis. Neurology 1996; 46:373-378.
23. Bot JC, Barkhof F. Spinal-cord MRI in multiple sclerosis: conventional and nonconventional MR techniques. Neuroimaging Clin N Am 2009;19:81-99.
24. Wolinsky JS. The PROMiSe trial: baseline data review and progress report. Mult Scler 2004;10(suppl 1):S65-S71.
25. Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008;358:676-688.
26. Rudick RA, Kappos L. Measuring disability in relapsingremitting MS. Neurology 2010;75:296-297.
27. Bielekova B, Kadom N, Fisher E, et al. MRI as a marker for disease heterogeneity in multiple sclerosis. Neurology 2005;65:1071-1076.
28. van den Elskamp IJ, Boden B, Dattola V, et al. Cerebral atrophy as outcome measure in short-term phase 2 clinical trials in multiple sclerosis. Neuroradiology 2010;52:875-881.
29. Galetta KM, Calabresi PA, Frohman EM, Balcer LJ. Optical coherence tomography (OCT): imaging the visual pathway as a model for neurodegeneration. Neurotherapeutics 2011; 8:117-132.
30. Thompson AJ, Kermode AG, Wicks D, et al. Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Ann Neurol 1991;29:53-62.
31. Ingle GT, Sastre-Garriga J, Miller DH, Thompson AJ. Is inflammation important in early PPMS? A longitudinal MRI study. J Neurol Neurosurg Psychiatry 2005;76:1255-1258..